Endocrine Abstracts

Introduction: Gestational diabetes mellitus (GDM) is a carbohydrate intolerance with onset or recognition during pregnancy. Timely screening and proper management of this condition is essencial to maximize pregnancy and neonatal outcomes.Methods: Retrospective analysis of all cases of GDM, and the respective new-borns, followed in our obstetrics unit between 2012 and 2015. Clinical and workup parameters were evaluated.Results: From...

Introduction: Gestational Diabetes Mellitus (GDM) is a pregnancy complication that has experienced a worldwide growth. The use of insulin has to be considered as it may be beneficial for both the mother and the new-born.Methods: Retrospective analysis of all cases of GDM, and the respective new-borns (NB), followed in our obstetrics unit between 2012 and 2015. Clinical and workup parameters were evaluated in 2 groups: GDM with no insulin therapy (GDMNIT)...

Introduction: Screening for gestational diabetes (GD) in the first trimester using fasting plasma glucose (FPG) ≥92 mg/dl is routinely performed in several countries. However, evidence on the benefits and harms of early universal screening, as well as the optimal cut-off of FPG, is conflicting. This results in lack of standardised screening and treatment approaches for GD worldwide.Aims: o compare the use of pharmacological treatment and pregnancy ...

Introduction: Women with gestational diabetes (GD) have an increased risk of developing future type 2 diabetes mellitus (T2DM). A reclassification oral glucose tolerance test (OGTT) is currently recomended in the postpartum period. However, most studies report a compliance rate below 50% and as low as 23%.Objectives: We aimed to study predictors of missing postpartum OGTT in women with GD.Materials and Methods: Retrospecti...

Introduction: Gestational diabetes (GD) is defined as a glucose intolerance firstly recognized during pregnancy and it is the severity of hyperglycaemia which is relevant to maternal and foetal risks. The American Diabetes Association (ADA) recommends screening before 15 weeks of gestation for women at risk, using standard diagnostic criteria, and defines early abnormal glucose metabolism as fasting glucose 110-125 mg/dl or HbA1c 5.9-6.4%. However, the benefit of treating wome...